SavedAdd your journal

Journals / Anatolian Current Medical Journal / 2023 / Cilt: 5 Sayı: 4

Does vitreous galactin-3, copeptin, and retina binding protein-4 concentrations change İn diabetic retinopathy?

Şerife Gülhan KONUK
Raşit KILIÇ
Merve ÇATAK
Alper GÜNEŞ
Muzaffer KATAR
Pages
411–415
Publication Date
2023-10-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results indicate that the concentrations of G-3, CP, and RBP-4 in the vitreous humor remain unchanged in both diabetic patients and those with proliferative diabetic retinopathy (DRP).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to investigate whether the concentrations of Galactin-3 (G-3), Copeptin (CP) and Retina Binding Protein-4 (RBP-4) are affected in the vitreous humor of patients with diabetic retinopathy (DR).
📊
Key Findings & Data:Methods: Thirty-six patients with diabetes mellitus (DM) were included in the study, consisting of 10 patients without DR and 26 patients with proliferative diabetic retinopathy (PDR).
💡
Conclusion & Impact:Conclusion: Our results indicate that the concentrations of G-3, CP, and RBP-4 in the vitreous humor remain unchanged in both diabetic patients and those with proliferative diabetic retinopathy (DRP).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Copeptin · Galactin-3 · Retina Binding Protein-4

Abstract

Objective: This study aimed to investigate whether the concentrations of Galactin-3 (G-3), Copeptin (CP) and Retina Binding Protein-4 (RBP-4) are affected in the vitreous humor of patients with diabetic retinopathy (DR). Methods: Thirty-six patients with diabetes mellitus (DM) were included in the study, consisting of 10 patients without DR and 26 patients with proliferative diabetic retinopathy (PDR). The control group comprised 15 patients who underwent vitrectomy for epiretinal membrane and macular hole surgeries. Vitreous CP, G-3, and RBP-4 concentrations were examined using the enzyme-linked immunosorbent assay (ELISA) method. The groups were compared internally Results: We did not observe any significant differences in the concentrations of G-3, CP and RBP-4 in the vitreous humor between diabetic patients and the control group (p=0.56, p=0.65 and p=0.11, respectively). When comparing vitreous samples of diabetic subgroups with and without DR findings to the control group, no significant differences were detected (p=0.51, p=0.66, and p=0.19, respectively). Conclusion: Our results indicate that the concentrations of G-3, CP, and RBP-4 in the vitreous humor remain unchanged in both diabetic patients and those with proliferative diabetic retinopathy (DRP).

🔖

Cite This Article

KONUK, Ş. G., KILIÇ, R., ÇATAK, M., GÜNEŞ, A., KATAR, M. (2023). Does vitreous galactin-3, copeptin, and retina binding protein-4 concentrations change İn diabetic retinopathy?. Anatolian Current Medical Journal, Cilt: 5 Sayı: 4, 411–415. https://ajindex.com/articles/968514

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Jakhotia S, Sivaprasad M, Shalini T, et al. Circulating levels of Hsp27 in microvascular complications of diabetes: prospects as a biomarker of diabetic nephropathy. J Diabetes Complications. 2018;32(2):221-225.
  2. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428-431.
  3. Do DV, Han G, Abariga SA, Sleilati G, Vedula SS, Hawkins BS. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2023;3(3):CD006127. Frank RN. Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol. 2015;22(2):151-156.
  4. Boss JD, Singh PK, Pandya HK, et al. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2017;58(12):5594-5603.
  5. Sciacchitano S, Lavra L, Morgante A, et al. Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int J Mol Sci. 2018;19(2):379. Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008;28(3):433-440.
  6. Hara A, Niwa M, Noguchi K, et al. Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules. 2020;10(3):389. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54(1):60-68.
  7. Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140:w13101. Quadro L, Blaner WS, Salchow DJ, et al. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. EMBO J. 1999;18(17):4633-4644.
  8. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17(1):24-38.
  9. Meeusen JW, Johnson JN, Gray A, et al. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem. 2015;48(18):1337-1340.
  10. Schindler EI, Szymanski JJ, Hock KG, Geltman EM, Scott MG. Short-and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with stable heart failure and healthy adults. Clin Chem. 2016;62(2):360-366.
  11. Baek JH, Kim SJ, Kang HG, et al. Galectin-3 activates PPARγ and supports white adipose tissue formation and high-fat diet-induced obesity. Endocrinology. 2015;156(1):147-156.
  12. Pang J, Rhodes DH, Pini M, et al.